Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Sales (2016 - 2026)

Ocular Therapeutix has reported Return on Sales over the past 13 years, most recently at 0.08% for Q1 2026.

  • For Q1 2026, Return on Sales fell 2.0% year-over-year to 0.08%; the TTM value through Mar 2026 reached 0.06%, down 2.0%, while the annual FY2025 figure was 0.05%, 2.0% down from the prior year.
  • Return on Sales for Q1 2026 was 0.08% at Ocular Therapeutix, down from 0.05% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q3 2023 and troughed at 0.08% in Q1 2026.
  • A 5-year average of 0.03% and a median of 0.02% in 2024 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: grew 2bps in 2022 and later fell -4bps in 2025.
  • Year by year, Return on Sales stood at 0.01% in 2022, then dropped by -4bps to 0.02% in 2023, then plummeted by -87bps to 0.03% in 2024, then tumbled by -72bps to 0.05% in 2025, then crashed by -70bps to 0.08% in 2026.
  • Business Quant data shows Return on Sales for OCUL at 0.08% in Q1 2026, 0.05% in Q4 2025, and 0.05% in Q3 2025.